Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WNTinib
- Development stage
- Preclinical
- Lead developer
- National Cancer Institute
- Modality
- Small Molecules
- Administration
- Oral, Topical, Subcutaneous, Intravenous, Intramuscular, Inhalation, Intranasal, Ophthalmic, Rectal, Sublingual, Buccal, Transdermal, Intradermal, Intraarticular, Intralesional, Intraperitoneal, Intra-arterial, Intravesical, Parenteral, Implant
01
Overview
WNTinib is a small molecule inhibitor developed by the National Cancer Institute (NCI) in collaboration with Bristol Myers Squibb (BMS). It specifically targets CTNNB1 (beta-catenin), a key component of the Wnt/beta-catenin signaling pathway, which is frequently mutated or dysregulated in various cancers. The drug is currently in the IND-enabling preclinical phase, with a primary focus on the treatment of hepatocellular carcinoma (HCC). By inhibiting CTNNB1-related signaling, WNTinib aims to suppress tumor growth and progression driven by aberrant Wnt pathway activation.
- Other names
- WNTinib
02
Targets
MAPK14 (p38 mitogen-activated protein kinase alpha)BRAF (B-Raf proto-oncogene, serine/threonine kinase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)MEKVEGFR-1 (Vascular endothelial growth factor receptor 1)PDE6D (Phosphodiesterase 6-delta)
Beyond the preview
Go deeper on WNTinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WNTinib.